NasdaqGS:MYOK

Stock Analysis Report

Executive Summary

MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

Rewards

Revenue is forecast to grow 67.33% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year



Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has MyoKardia's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MYOK's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.0%

MYOK

-1.9%

US Pharmaceuticals

1.5%

US Market


1 Year Return

64.9%

MYOK

6.7%

US Pharmaceuticals

20.1%

US Market

Return vs Industry: MYOK exceeded the US Pharmaceuticals industry which returned 6.7% over the past year.

Return vs Market: MYOK exceeded the US Market which returned 20.1% over the past year.


Shareholder returns

MYOKIndustryMarket
7 Day-2.0%-1.9%1.5%
30 Day-4.5%-2.8%1.4%
90 Day25.3%8.1%8.7%
1 Year64.9%64.9%9.4%6.7%22.7%20.1%
3 Year452.2%452.2%28.6%19.4%50.1%40.5%
5 Yearn/a24.6%11.8%73.1%54.1%

Price Volatility Vs. Market

How volatile is MyoKardia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MyoKardia undervalued compared to its fair value and its price relative to the market?

7.19x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: MYOK ($70.4) is trading above our estimate of fair value ($2.54)

Significantly Below Fair Value: MYOK is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MYOK is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: MYOK is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MYOK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MYOK is overvalued based on its PB Ratio (7.2x) compared to the US Pharmaceuticals industry average (3x).


Next Steps

Future Growth

How is MyoKardia forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

48.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MYOK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MYOK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MYOK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MYOK's revenue (67.3% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: MYOK's revenue (67.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MYOK is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has MyoKardia performed over the past 5 years?

-47.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MYOK is currently unprofitable.

Growing Profit Margin: MYOK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MYOK is unprofitable, and losses have increased over the past 5 years at a rate of -47.2% per year.

Accelerating Growth: Unable to compare MYOK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYOK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.4%).


Return on Equity

High ROE: MYOK has a negative Return on Equity (-51.54%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is MyoKardia's financial position?


Financial Position Analysis

Short Term Liabilities: MYOK's short term assets ($424.7M) exceed its short term liabilities ($44.1M).

Long Term Liabilities: MYOK's short term assets ($424.7M) exceed its long term liabilities ($2.2M).


Debt to Equity History and Analysis

Debt Level: MYOK is debt free.

Reducing Debt: MYOK has not had any debt for past 5 years.


Balance Sheet

Inventory Level: MYOK has a low level of unsold assets or inventory.

Debt Coverage by Assets: MYOK's debt is not covered by short term assets (assets are -5817.7x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MYOK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MYOK has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of -47.4% each year.


Next Steps

Dividend

What is MyoKardia's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.7%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate MYOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MYOK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MYOK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYOK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYOK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Tassos Gianakakos (46yo)

6.3yrs

Tenure

US$8,974,780

Compensation

Mr. Tassos Anastasios Gianakakos has been the President and Chief Executive Officer at MyoKardia, Inc., since October 2013. Mr. Gianakakos has more than 17 years of broad-based biopharmaceutical expertise  ...


CEO Compensation Analysis

Compensation vs Market: Tassos's total compensation ($USD8.97M) is above average for companies of similar size in the US market ($USD4.88M).

Compensation vs Earnings: Tassos's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Tassos Gianakakos
President6.3yrsUS$8.97mno data
Taylor Harris
Chief Financial Officer1.8yrsUS$4.43m0.011% $351.5k
Robert McDowell
Chief Scientific Officer2.3yrsUS$2.56m0.012% $378.8k
Cynthia Ladd
General Counsel2.1yrsUS$4.68m0.0062% $200.8k
Jake Bauer
Chief Business Officer1.8yrsUS$2.01m0.12% $4.0m
June Lee
Executive Officer2.3yrsUS$3.47m0.0090% $292.2k
Leslie Leinwand
Co-Founder8.1yrsno datano data
Christine Seidman
Co-Founder8.1yrsno datano data
Jonathan Seidman
Co-Founder8.1yrsno datano data
James Spudich
Co-Founder8.1yrsno datano data

4.3yrs

Average Tenure

53yo

Average Age

Experienced Management: MYOK's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Tassos Gianakakos
President6.3yrsUS$8.97mno data
Mark Perry
Lead Independent Director0yrsUS$420.88k0.055% $1.8m
Kimberly Popovits
Independent Director2.9yrsUS$376.88kno data
Wendy Yarno
Independent Director2.9yrsUS$385.88k0.0031% $99.3k
Mary Cranston
Independent Director3.8yrsUS$395.88kno data
David Meeker
Independent Director2.8yrsUS$378.38kno data
Sunil Agarwal
Independent Director3.9yrsUS$388.38kno data

3.4yrs

Average Tenure

63yo

Average Age

Experienced Board: MYOK's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MYOK insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.3%.


Top Shareholders

Company Information

MyoKardia, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MyoKardia, Inc.
  • Ticker: MYOK
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.254b
  • Shares outstanding: 46.23m
  • Website: https://www.myokardia.com

Number of Employees


Location

  • MyoKardia, Inc.
  • 333 Allerton Avenue
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYOKNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2015
9MKDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2015
MYOK *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNOct 2015

Biography

MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 00:39
End of Day Share Price2020/02/14 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.